News by subject: Clinical Study

Annovis Bio, Inc.  ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation...

Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and safety results from the X-TOLE Phase 2b randomized clinical trial of XEN1101, a...

Biomea Fusion, Inc. ("Biomea") , a clinical-stage...

Datacubed Health, a leading global provider of innovative solutions for patient engagement and data collection in clinical trials, is excited to announce the official launch of its eClinical platform app in China. This milestone achievement...

Small...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (A?) monoclonal antibody LEQEMBI® Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved...

Arch Biopartners Inc., ("Arch" or the "Company") , announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting...

Optimi Health Corp. (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature...

Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating...

NurExone Biologic Inc. (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing...

ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of...

Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount Sinai, in New York, NY, for the use of allogenic hematopoietic stem cell expansion and transplantation...

Building on its long-standing commitment to advancing health equity, and specifically clinical equality, IPG Health formally launched an industry-first offering designed to help pharma and healthcare companies diversify their clinical trials and...

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for all patients across important subscales of Seizure...

Lifezone Metals Limited ("Lifezone Metals" or the "Company") , a modern metals company creating value across the battery metals supply chain from mine to metals production and recycling, is pleased to announce an update on its resource definition...

Clinical-stage pharmaceutical company ENA Respiratory...

Organovo Holdings, Inc. (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease,...

Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA I&T in patients with histologically-proven metastatic prostate cancer. The study has met the...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has...

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy...

Biogen Inc. and Sage Therapeutics, Inc. (Nasdaq:...

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") , a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2...

New research looking at the mental health and eating behaviours of patients 1-year after bariatric surgery has found that a short, 7-session telephone cognitive behavioural therapy (Tele-CBT) intervention is helpful in reducing symptoms of...

A recent survey conducted by Essilor®, part of EssilorLuxottica a leading global eyecare and eyewear provider, revealed that children's eye health and vision are often overlooked by parents amidst the many other concerns they face.1 The survey, which...

Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based...

IntelGenx Corp.  (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a ("BUENA") clinical trial in patients with mild to moderate Alzheimer's Disease ("AD"). The...

Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of the...

Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 69 patients for the Company's Tigris trial, a Phase 3...

IntelGenx Corp.  (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned...

The AIDS Clinical Trials Group (ACTG), a global clinical trials network focused on HIV, tuberculosis, hepatitis B and emerging infectious diseases, today announced the publication of "Pitavastatin to Prevent Cardiovascular Disease in HIV Infection"...

Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in...

PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is thrilled that ? following pre-submission meetings held...

NurExone Biologic Inc. (NRX.V) ("NurExone" or the "Company") is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved...

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the...

Achieve Life Sciences, Inc. , today announced the publication in JAMA of the results from the Phase 3 ORCA-2 randomized placebo-controlled...

VANCOUVER, BC ? July 10, 2023 ? Praxis Spinal Cord Institute is delighted to announce the allocation of more than $4 million in grant awards to support 33 spinal cord injury (SCI) initiatives across Canada. Projects funded involve SCI translational...

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A....

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced results of the Company's Phase 3 clinical trial...

Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the opening of three new clinical trials sites, the University of Alabama at Birmingham...

Small...

Genenta Science , a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S....

Arch Biopartners Inc., ("Arch" or the "Company") , announced today that it received a "Study May...

BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis...

Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company's follow-on study designed to build on...